Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Lexicon Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Lexicon Pharmaceuticals, Inc.’s stock price such as:

• Lexicon Pharmaceuticals, Inc.’s current stock price and volume
• Why Lexicon Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for LXRX from analysts
• LXRX’s stock price momentum as measured by its relative strength

About Lexicon Pharmaceuticals, Inc. (LXRX)

Before we jump into Lexicon Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Want to learn more about Lexicon Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Lexicon Pharmaceuticals, Inc..

Lexicon Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of March 31, 2026, 4:00 PM, CST, Lexicon Pharmaceuticals, Inc.’s stock price was $1.560.

Lexicon Pharmaceuticals, Inc. is up 3.31% from its previous closing price of $1.510.

During the last market session, Lexicon Pharmaceuticals, Inc.’s stock traded between $1.520 and $1.590. Currently, there are approximately 363.43 million shares outstanding for Lexicon Pharmaceuticals, Inc..

Lexicon Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Lexicon Pharmaceuticals, Inc. Stock Price History

Lexicon Pharmaceuticals, Inc.’s (LXRX) price is currently up 6.12% so far this month.

During the month of March, Lexicon Pharmaceuticals, Inc.’s stock price has reached a high of $1.790 and a low of $1.420.

Over the last year, Lexicon Pharmaceuticals, Inc. has hit prices as high as $1.830 and as low as $0.360. Year to date, Lexicon Pharmaceuticals, Inc.’s stock is up 35.65%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Lexicon Pharmaceuticals, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 31, 2026, there were 0 analysts who downgraded Lexicon Pharmaceuticals, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Lexicon Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Lexicon Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Lexicon Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Lexicon Pharmaceuticals, Inc. (LXRX) by visiting AAII Stock Evaluator.

Relative Price Strength of Lexicon Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 31, 2026, Lexicon Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 36.90%, which translates to a Momentum Score of 96 and is considered to be Very Strong.

Want to learn more about how Lexicon Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Lexicon Pharmaceuticals, Inc. Stock Price: Bottom Line

As of March 31, 2026, Lexicon Pharmaceuticals, Inc.’s stock price is $1.560, which is up 3.31% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Lexicon Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.